10:10 AM EDT, 07/30/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said Wednesday it has signed an exclusive collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan.

Viridian said it will receive an upfront payment of $70 million and may get up to an additional $315 million in milestone payments as well as tiered royalties on net sales in the country in the "20s to mid-30s percent."

Kissei will be in charge of all development, regulatory, and commercialization activities, and related costs, in Japan, Viridian said.

Both molecules are used for the potential treatment of people with thyroid eye disease, the company said.

Viridian shares were rising 5.7% in recent trading.

Price: 17.90, Change: +1.11, Percent Change: +6.60